Market Overview:
The global RNA vaccines market is expected to grow at a CAGR of 16.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases and cancer, and the rising demand for preventive vaccines. The market is segmented on the basis of type, application, and region. On the basis of type, the global RNA vaccines market is segmented into individualized cancer treatment MRNA vaccine, infectious disease treatment MRNA vaccine, infection prevention MRNA vaccine, and other types of RNA vaccines. The individualized cancer treatment MRNA vaccine segment is expected to grow at a CAGR of 17% during the forecast period from 2018 to 2030. This growth can be attributed to increasing investments by pharmaceutical companies in this area and rising demand for personalized medicines for treating various cancers. On the basis of application,the global RNA vaccines market is divided into infectious diseases such as HIV/AIDS,, hepatitis B &C,, tuberculosis,, malaria,, dengue fever),cancer (such as breast cancer),and other applications including RSV infections,.
Product Definition:
RNA vaccines are created from pieces of the virus' genetic material. These vaccines help the body create immunity against infections by the virus.
-Ease of production: Unlike traditional vaccine technologies that require propagation of viruses in living cells, RNA vaccines can be produced very easily in a test tube or other laboratory setting.
-Possibility to target multiple strains: Because RNA is not limited by the need to conform to a protein shell, it is possible to create an RNA vaccine that targets many different strains of a virus simultaneously.
-Ability to evade detection by the immune system: One potential downside of using viral particles as a vaccine is that they can be recognized and eliminated by the immune system before they have time to provoke an effective response.
Individualized Cancer Treatment MRNA Vaccine:
Ans: The International Society for Biological and Environmental Reprogramming (ISBGR), Germany, organized a world congress on reprogramming technologies for cancer management & treatment in 2010. This has resulted in increased awareness levels amongst the researchers and scientists operating in this field of medicine.
Infectious Disease Treatment MRNA Vaccine:
Infectious disease treatment MRNA vaccine and it's usage in RNA vaccines market: The global infectious disease treatment MRNA vaccine and it's usage in RNA vaccines market size was valued at USD 8.5 billion in 2015. Increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders & respiratory diseases is expected to boost the demand for therapeutic molecules including recombinant nucleic acid drugs over the forecast period.
Application Insights:
Based on the application, the market is segmented into infectious disease, cancer and other. The other applications include immunization against autoimmune diseases, allergies and asthma. The growing usage of gene therapy to treat these chronic conditions has led to an increased demand for individualized vaccines that can be used in a personalized manner. This is anticipated to drive the demand for RNA-based vaccines over the forecast period.
The increasing prevalence of cancer across various regions coupled with rising awareness about its early diagnosis is expected to boost product adoption in this segment over the forecast period. For instance, according to data published by WHO in 2018 regarding global cancer incidence rates; it was estimated that around 14 million new cases were diagnosed worldwide every year along with 9 million deaths due largely without a doubt as well as cervical cancers caused by human papillomavirus (HPV).
Regional Analysis:
North America dominated the global RNA vaccines market in 2017. This is due to presence of a large number of players, advanced healthcare infrastructure and high adoption rate for novel therapeutics in this region. Moreover, increasing focus on infectious diseases and cancer as major public health concerns are also driving the demand for these vaccines in North America.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about various types of cancer among Asian population coupled with growing disposable income levels especially in China & India which are amongst top five countries globally regarding GDP per capita at purchasing power parity (PPP). These factors along with government support are anticipated to boost regional market growth during the forecast period.
Growth Factors:
- Increasing demand for preventive healthcare measures: The global population is aging and this has increased the demand for preventive healthcare measures. This is expected to drive the growth of the RNA vaccines market in the coming years.
- Technological advancements: The development of new technologies has led to the introduction of novel RNA vaccines that are more effective and have a longer shelf life. This is expected to boost the growth of this market in the near future.
- Rising prevalence of infectious diseases: The incidence of infectious diseases is on the rise, which has led to an increase in demand for effective vaccines against these diseases. This is anticipated to fuel growth in this market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
RNA Vaccines Market Research Report
By Type
Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine,
By Application
Infectious Disease, Cancer, Other,
By Companies
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global RNA Vaccines Market Report Segments:
The global RNA Vaccines market is segmented on the basis of:
Types
Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Disease, Cancer, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Highlights of The RNA Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Individualized Cancer Treatment MRNA Vaccine
- Infectious Disease Treatment MRNA Vaccine
- Infection Prevention MRNA Vaccine
- By Application:
- Infectious Disease
- Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the RNA Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
RNA vaccines are a type of vaccine that uses pieces of RNA as the basis for immunity. This type of vaccine is thought to work better than traditional vaccines because it can target specific genes and proteins in the virus.
Some of the major players in the rna vaccines market are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology.
The rna vaccines market is expected to grow at a compound annual growth rate of 16.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. RNA Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. RNA Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. RNA Vaccines Market - Supply Chain
4.5. Global RNA Vaccines Market Forecast
4.5.1. RNA Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. RNA Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. RNA Vaccines Market Absolute $ Opportunity
5. Global RNA Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. RNA Vaccines Market Size and Volume Forecast by Type
5.3.1. Individualized Cancer Treatment MRNA Vaccine
5.3.2. Infectious Disease Treatment MRNA Vaccine
5.3.3. Infection Prevention MRNA Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global RNA Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. RNA Vaccines Market Size and Volume Forecast by Application
6.3.1. Infectious Disease
6.3.2. Cancer
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global RNA Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. RNA Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global RNA Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. RNA Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global RNA Vaccines Demand Share Forecast, 2019-2026
9. North America RNA Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America RNA Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America RNA Vaccines Market Size and Volume Forecast by Application
9.4.1. Infectious Disease
9.4.2. Cancer
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America RNA Vaccines Market Size and Volume Forecast by Type
9.7.1. Individualized Cancer Treatment MRNA Vaccine
9.7.2. Infectious Disease Treatment MRNA Vaccine
9.7.3. Infection Prevention MRNA Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America RNA Vaccines Demand Share Forecast, 2019-2026
10. Latin America RNA Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America RNA Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America RNA Vaccines Market Size and Volume Forecast by Application
10.4.1. Infectious Disease
10.4.2. Cancer
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America RNA Vaccines Market Size and Volume Forecast by Type
10.7.1. Individualized Cancer Treatment MRNA Vaccine
10.7.2. Infectious Disease Treatment MRNA Vaccine
10.7.3. Infection Prevention MRNA Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America RNA Vaccines Demand Share Forecast, 2019-2026
11. Europe RNA Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe RNA Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe RNA Vaccines Market Size and Volume Forecast by Application
11.4.1. Infectious Disease
11.4.2. Cancer
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe RNA Vaccines Market Size and Volume Forecast by Type
11.7.1. Individualized Cancer Treatment MRNA Vaccine
11.7.2. Infectious Disease Treatment MRNA Vaccine
11.7.3. Infection Prevention MRNA Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe RNA Vaccines Demand Share, 2019-2026
12. Asia Pacific RNA Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific RNA Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific RNA Vaccines Market Size and Volume Forecast by Application
12.4.1. Infectious Disease
12.4.2. Cancer
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific RNA Vaccines Market Size and Volume Forecast by Type
12.7.1. Individualized Cancer Treatment MRNA Vaccine
12.7.2. Infectious Disease Treatment MRNA Vaccine
12.7.3. Infection Prevention MRNA Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific RNA Vaccines Demand Share, 2019-2026
13. Middle East & Africa RNA Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa RNA Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa RNA Vaccines Market Size and Volume Forecast by Application
13.4.1. Infectious Disease
13.4.2. Cancer
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa RNA Vaccines Market Size and Volume Forecast by Type
13.7.1. Individualized Cancer Treatment MRNA Vaccine
13.7.2. Infectious Disease Treatment MRNA Vaccine
13.7.3. Infection Prevention MRNA Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa RNA Vaccines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global RNA Vaccines Market: Market Share Analysis
14.2. RNA Vaccines Distributors and Customers
14.3. RNA Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Moderna Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CureVac
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Translate Bio
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. BioNTech
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sangamo Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Argos Therapeutics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. In-Cell-Art
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. eTheRNA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ethris
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Tiba Biotechnology
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook